Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET
Company Participants
Dan Dischner - Senior Vice President of Corporate Communications
William Peters - Chief Financial Officer
Tony Marrs - Executive Vice President, Regulatory Affairs and Clinical Operations
Conference Call Participants
Ekaterina Knyazkova - JPMorgan
David Amsellem - Piper Sandler
Jason Gerberry - Bank of America
Tim Chiang - Capital One
Serge Belanger - Needham & Company
Glen Santangelo - Jefferies
Operator
Greetings, and welcome to the Amphastar Pharmaceuticals Second Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]
Please note that certain statements made during this call regarding matters that are not historical facts, including, but not limited to management's outlook or predictions for future periods are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled forward-looking statements in the press release issued today in the presentation on the company's website. Also, please refer to our SEC filings, which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance.
We will also discuss certain non-GAAP measures and for information on our use of these measures and reconciliations to U.S. GAAP may be found in our earnings release. Please note, this conference is being recorded.
Our speakers today are Mr. Bill Peters, CFO; Mr. Dan Dischner, Senior Vice President of Corporate Communications; and Mr. Tony Marrs, Executive Vice President of Regulatory Affairs and Clinical Operations.
I will now turn the call over to your host, Mr. Dan Dischner, Senior Vice President of Corporate Communications. Dan, you may begin.
Dan Dischner
Thank you, Paul. Good afternoon, and thanks for joining us for our second quarter earnings call of 2024. Joining me today will be Bill Peters, CFO and Executive Vice President of Finance; and Tony Marrs, Executive Vice President of Regulatory Affairs and Clinical Operations.
It has now been over a year since the successful acquisition of BAQSIMI, underscoring Amphastar's strategic focus on expanding our portfolio with proprietary products, biosimilars and complex products. This quarter, BAQSIMI has emerged as a key driver, achieving impressive worldwide sales of $38.5 million for the quarter, representing a 10% increase compared to the same period last year and highlighting this product's growth.